Imunofan® (Imunofan®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceArginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginineArginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine
Similar drugsTo uncover
  • Imunofan®
    spray nazal. 
    BIONOKS NPP, LLC     Russia
  • Imunofan®
    solution w / m PC 
    BIONOKS NPP, LLC     Russia
  • Imunofan®
    suppositories rect. 
    BIONOKS NPP, LLC     Russia
    • Dosage form: & nbsprectal suppositories
    Composition:

    Active substance: imunofan 100 mg, Excipients (glycine 5 mg, polysorbate 80 (Tween 80) 1% of the weight of the suppository, water purified 25 mg, hard fat until a suppository with a weight of 1.2 to 1.5 g).

    Description:

    Homogeneous suppositories from white to white with a yellowish hue of color, torpedo shape. A weak specific odor is allowed.

    Pharmacotherapeutic group:Immunomodulating agent
    ATX: & nbsp

    L.03.A.X   Other immunostimulants

    Pharmacodynamics:

    The drug has an immunoregulatory, detoxicating, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the oxidative-antioxidant reaction of the organism and inhibition of multiple drug resistance mediated by proteins of the transmembrane transport pump of the cell.

    Pharmacokinetics:

    The drug begins to develop within 2-3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

    During the fast phase (duration - up to 2 - 3 days) detoxification effect is manifested primarily - antioxidant protection of the body is enhanced by stimulation of the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the disintegration of cell membrane phospholipids, and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol and the production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

    During the middle phase (beginning 2-3 days, duration - up to 7 - 10 days), there is an intensification of the reactions of phagocytosis and death of intracellular bacteria and viruses.

    During the slow phase (starts to develop on 7 - 10 days, duration of up to 4 months) immunoregulatory effect of Imunofan is manifested - restoration of the disturbed parameters of cellular and humoral immunity.During this period, the normalization of the immunoregulatory index is observed, an increase in the production of specific antibodies is noted. The influence of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of certain therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reactive antibodies of the class IgE and does not enhance the immediate-type hypersensitivity reaction; Imunofan stimulates education IgA with his congenital insufficiency.

    Imunofan effectively suppresses multiple drug the stability of tumor cells and increases their sensitivity to the action of cytotoxic drugs.

    Indications:

    Applied in adults and children over two years for the prevention and treatment of immunodeficiency and toxic conditions, chronic inflammatory diseases of various etiologies. In adults, as an adjuvant for vaccination against bacterial and viral infections.

    Contraindications:

    Hypersensitivity, pregnancy, complicated Rh-conflict, children under 2 years.

    Pregnancy and lactation:

    In pregnancy and during breastfeeding apply only if the intended benefit to the mother exceeds the potential risk to the fetus and the baby.

    Dosing and Administration:

    Rectally. Single dose and daily - 100 mcg (1 suppository).

    In the treatment of cancer patients in the scheme of radical combined treatment (chemoradiotherapy and surgery):

    - once, daily, treatment 8-10 suppositories before chemoradiotherapy and surgery followed by continuation of the course throughout the treatment period.

    In patients with a common tumor process (III - IV stage) of different localization in the form of complex or symptomatic therapy:

    - once, daily, treatment course 8 - 10 suppositories, with a break of 15-20 days and a repetition of courses during the entire period of subsequent treatment.

    In children with malignant diseases of the hematopoietic and lymphoid tissue:

    - 1 time per day, daily, treatment course 10-20 suppositories. The administration of the drug should be carried out throughout the course of chemoradiotherapy and after completion of the course to prevent the development of toxicosis.

    In the complex therapy of children with papillomatosis of the larynx and oropharynx:

    - 1 time per day, daily, treatment course 10 suppositories.

    For opportunistic infections (cytomegalovirus and herpetic infection, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis):

    - 1 time per day, daily, course of treatment 15-20 suppositories.

    In the complex therapy of HIV infection:

    - 1 time per day, daily, course of treatment 15-20 suppositories. If necessary, repeat courses should be conducted in 2-4 weeks.

    In chronic viral hepatitis and chronic brucellosis:

    - 1 time per day, daily, course of treatment 15-20 suppositories, in order to prevent relapse, repeat courses should be conducted after 2-3 months.

    With diphtheria:

    - 1 time per day, daily, course of treatment 8-10 suppositories. With diphtheria bacteriocarrier -1 times in 3 days - 3-5 suppositories.

    When treating burns III-IV degree with the phenomena of toxemia, septicotoxemia, in surgical patients with septic endocarditis, long-term non-healing wounds of the extremities, purulent-septic complications:

    - 1 time per day, daily, course of treatment 7-10 suppositories, if necessary, the course of the drug should be continued to 20 suppositories.

    With broncho-obstructive syndrome, cholecystopancreatitis, rheumatoid arthritis:

    - 1 time in 3 days, course of treatment 8-10 suppositories, if necessary, the course should continue to 20 suppositories at the same interval.

    In the treatment of psoriasis:

    -1 times a day, daily, treatment 15-20 suppositories.

    In adults, the vaccination schedule is one time per day of vaccination.

    Side effects:

    Allergic reactions to the components of the drug.

    Interaction:

    The action of Imunofan does not depend on the products of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroidal and non-steroidal) drugs.

    Special instructions:

    As a result of the activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles, mechanisms.

    Form release / dosage:

    Suppositories rectal by 100 mcg.

    Packaging:For 5 or 10 suppositories in a contiguous cell package. 1 or 2 contour squares in a pack of cardboard.
    Storage conditions:

    In the dark place at a temperature of 2 to 8 ° C. Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N000106 / 04
    Date of registration:18.08.2010 / 19.05.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:BIONOKS NPP, LLC BIONOKS NPP, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp06.11.2017
    Illustrated instructions
      Instructions
      Up